Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retaspimycin - Infinity Pharmaceuticals

Drug Profile

Retaspimycin - Infinity Pharmaceuticals

Alternative Names: IPI-504; MEDI-561; Retaspimycin hydrochloride

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Massachusetts General Hospital
  • Class Antineoplastics; Benzoquinones; Macrocyclic lactams; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastrointestinal stromal tumours; HER2 positive breast cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 01 Oct 2014 Infinity Pharmaceuticals completes a phase I/II trial in Non-small cell lung cancer with KRAS mutation (combination therapy, second-line therapy) in USA (NCT01427946)
  • 01 Apr 2014 Infinity Pharmaceuticals completes a phase II trial in Non-small cell lung cancer in Taiwan, Russia, Romania, South Korea, Hungary and USA (NCT01362400)
  • 25 Sep 2013 Discontinued - Phase-II for Non-small cell lung cancer in Hungary (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top